CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. Collaboration and Option Agreement Between MORPHIC...Collaboration and Option Agreement • May 22nd, 2019 • Morphic Holding, Inc. • Pharmaceutical preparations • New York
This Collaboration and Option Agreement (this “Agreement”) is made and entered into as of October 16, 2018, 2018 (the “Execution Date”) by and between Morphic Therapeutic, Inc., a Delaware corporation (“Morphic”) and AbbVie Biotechnology Ltd, a corporation organized under the laws of Bermuda having its principal place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (“AbbVie”). Morphic and AbbVie are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
LEASE OF PREMISES AT 35 GATEHOUSE DRIVE, WALTHAM, MASSACHUSETTS FROM ASTRAZENECA PHARMACEUTICALS LIMITED PARTNERSHIP TO MORPHIC ROCK THERAPEUTIC, INC.Lease • May 22nd, 2019 • Morphic Holding, Inc. • Pharmaceutical preparations • Delaware
The following is a summary of certain basic terms of this Lease which is intended for the convenience and reference of the parties. Capitalized terms used, but not defined, in this Summary of Basic Terms, have their defined meanings in this Lease. In addition, some of the following items or terms are incorporated into this Lease by reference to the item or term or to this “Summary of Basic Terms”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BETWEEN CHILDREN’S...Exclusive License Agreement • May 22nd, 2019 • Morphic Holding, Inc. • Pharmaceutical preparations • Massachusetts
RESEARCH COLLABORATION AND OPTION AGREEMENT between JANSSEN PHARMACEUTICALS, INC. and MORPHIC THERAPEUTIC, INC. DATED: FEBRUARY 15, 2019Research Collaboration and Option Agreement • May 22nd, 2019 • Morphic Holding, Inc. • Pharmaceutical preparations • New York
This Research Collaboration and Option Agreement (this “Agreement”), dated as of February , 2019 (the “Effective Date”), is made by and between Morphic Therapeutic, Inc. having an office at 35 Gatehouse Drive A2, Waltham, MA 02451 92121 (“Morphic”), and Janssen Pharmaceuticals, Inc. having an office at 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (“Janssen”). Each of Morphic and Janssen may be referred to herein as a “Party” or together as the “Parties.”
Collaboration AgreementCollaboration Agreement • May 22nd, 2019 • Morphic Holding, Inc. • Pharmaceutical preparations • Massachusetts
This COLLABORATION AGREEMENT (“Agreement”), dated as of June 10, 2015, is made by and between Morphic Rock Therapeutic, Inc. (“Client”), a Delaware corporation with offices at 1000 Winter Street, Suite 3350, Waltham, MA 02451 and SCHRÖDINGER, LLC (“Schrödinger”), a Delaware limited liability company, with offices at 120 West 45th Street, 17th Floor, New York, New York 10036.
